These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25762124)

  • 1. The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
    Diamond E; Garcias Mdel C; Karir B; Tagawa ST
    Curr Treat Options Oncol; 2015 Feb; 16(2):9. PubMed ID: 25762124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic prostate cancer in 2015: The new and the old that is new again.
    Graff JN; Beer TM
    Nat Rev Clin Oncol; 2016 Feb; 13(2):73-4. PubMed ID: 26718107
    [No Abstract]   [Full Text] [Related]  

  • 5. Cabazitaxel for castration-resistant prostate cancer.
    Shigeta K; Miura Y; Naito Y; Takano T
    Lancet; 2011 Jan; 377(9760):121; author reply 122-3. PubMed ID: 21215876
    [No Abstract]   [Full Text] [Related]  

  • 6. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
    Protheroe A
    Nat Clin Pract Oncol; 2005 Feb; 2(2):68-9. PubMed ID: 16264873
    [No Abstract]   [Full Text] [Related]  

  • 7. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
    Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
    Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
    Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
    Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
    Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy in Prostate Cancer.
    Hurwitz M
    Curr Oncol Rep; 2015 Oct; 17(10):44. PubMed ID: 26216506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
    Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
    Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in treating advanced disease.
    Petrylak DP
    Am J Manag Care; 2013 Dec; 19(18 Suppl):s366-75. PubMed ID: 24494691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabazitaxel for castration-resistant prostate cancer.
    Froehner M; Wirth MP
    Lancet; 2011 Jan; 377(9760):121-2; author reply 122-3. PubMed ID: 21215875
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemotherapy for metastatic castrate-sensitive prostate cancer.
    Miller RE; Sweeney CJ
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):139-44. PubMed ID: 26976365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer.
    Ceresoli GL; De Vincenzo F; Sauta MG; Bonomi M; Zucali PA
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):374-80. PubMed ID: 26222275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience.
    Cicero G; De Luca R
    Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):325-31. PubMed ID: 21528780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.